Argus Investors' Counsel, Inc. Amgen Inc Transaction History

Argus Investors' Counsel, Inc.

$148 Million
Q3 2024

A detailed history of Argus Investors' Counsel, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Argus Investors' Counsel, Inc. holds 3,826 shares of AMGN stock, worth $1.07 Million. This represents 0.83% of its overall portfolio holdings.

Number of Shares

3,826

Previous 4,747 19.4%

Holding current value

$1.07 Million

Previous $1.48 Million 16.93%

% of portfolio

0.83%

Previous 0.92%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$309.38 - $337.38 $284,938 - $310,726	-921 Reduced 19.4%	3,826 $1.23 Million
Q2 2024 Jul 22, 2024	BUY	$262.75 - $319.31 $1.25 Million - $1.52 Million	4,747 New	4,747 $1.48 Million
Q1 2024 Apr 24, 2024	SELL	$268.87 - $324.56 $174,227 - $210,314	-648 Reduced 10.31%	5,638 $1.6 Million
Q4 2023 Jan 26, 2024	BUY	$255.7 - $288.46 $2,301 - $2,596	9 Added 0.14%	6,286 $1.81 Million
Q3 2023 Oct 17, 2023	BUY	$218.65 - $271.46 $38,701 - $48,048	177 Added 2.9%	6,277 $1.69 Million
Q2 2023 Jul 20, 2023	BUY	$214.27 - $253.37 $38,568 - $45,606	180 Added 3.04%	6,100 $1.35 Million
Q3 2022 Oct 18, 2022	SELL	$224.46 - $253.15 $439,941 - $496,174	-1,960 Reduced 24.87%	5,920 $1.33 Million
Q2 2022 Jul 22, 2022	SELL	$230.71 - $256.74 $91,130 - $101,412	-395 Reduced 4.77%	7,880 $1.92 Million
Q1 2022 May 04, 2022	SELL	$219.27 - $242.57 $433,277 - $479,318	-1,976 Reduced 19.28%	8,275 $2 Million
Q4 2021 Jan 25, 2022	SELL	$198.88 - $227.6 $9,546 - $10,924	-48 Reduced 0.47%	10,251 $2.31 Million
Q3 2021 Oct 20, 2021	SELL	$212.27 - $248.7 $1.16 Million - $1.36 Million	-5,466 Reduced 34.67%	10,299 $2.19 Million
Q2 2021 Jul 30, 2021	SELL	$233.58 - $259.14 $223,068 - $247,478	-955 Reduced 5.71%	15,765 $3.84 Million
Q1 2021 Apr 19, 2021	SELL	$221.91 - $258.6 $115,171 - $134,213	-519 Reduced 3.01%	16,720 $4.16 Million
Q4 2020 Jan 27, 2021	SELL	$216.38 - $257.67 $563,453 - $670,972	-2,604 Reduced 13.12%	17,239 $3.96 Million
Q3 2020 Oct 30, 2020	BUY	$234.65 - $260.95 $290,966 - $323,578	1,240 Added 6.67%	19,843 $5.04 Million
Q2 2020 Jul 27, 2020	SELL	$197.81 - $242.74 $68,442 - $83,988	-346 Reduced 1.83%	18,603 $4.39 Million
Q1 2020 Apr 24, 2020	SELL	$182.24 - $241.7 $96,404 - $127,859	-529 Reduced 2.72%	18,949 $3.84 Million
Q4 2019 Jan 17, 2020	SELL	$189.21 - $243.2 $393,556 - $505,856	-2,080 Reduced 9.65%	19,478 $4.7 Million
Q3 2019 Oct 17, 2019	SELL	$174.11 - $208.62 $413,511 - $495,472	-2,375 Reduced 9.92%	21,558 $4.17 Million
Q2 2019 Jul 10, 2019	BUY	$166.7 - $195.41 $4.29 Million - $5.03 Million	25,720 Added 116.14%	47,866 $8.82 Million
Q2 2019 Jul 10, 2019	SELL	$166.7 - $195.41 $3.99 Million - $4.68 Million	-23,933 Reduced 50.0%	23,933 $4.41 Million
Q1 2019 Apr 16, 2019	SELL	$180.87 - $203.88 $7,053 - $7,951	-39 Reduced 0.18%	22,146 $4.21 Million
Q4 2018 Feb 06, 2019	SELL	$178.4 - $208.25 $449,924 - $525,206	-2,522 Reduced 10.21%	22,185 $4.32 Million
Q3 2018 Oct 16, 2018	SELL	$185.29 - $208.89 $67,630 - $76,244	-365 Reduced 1.46%	24,707 $0
Q2 2018 Jul 19, 2018	BUY	$166.05 - $186.51 $213,208 - $239,478	1,284 Added 5.4%	25,072 $4.63 Million
Q1 2018 May 15, 2018	BUY	$169.43 - $198.0 $87,087 - $101,772	514 Added 2.21%	23,788 $4.44 Million
Q4 2017 Jan 23, 2018	SELL	$168.79 - $188.59 $86,758 - $96,935	-514 Reduced 2.16%	23,274 $4.05 Million
Q3 2017 Oct 06, 2017	BUY	$167.29 - $191.0 $3.98 Million - $4.54 Million	23,788	23,788 $4.44 Million

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Argus Investors' Counsel, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Argus Investors' Counsel, Inc. with notifications on news.

Account

Argus Investors' Counsel, Inc. Amgen Inc Transaction History